Funding for this research was provided by:
Dermatology Foundation (Pediatric Dermatology Career Development Award)
Society for Pediatric Dermatology (Weston Award)
Article History
First Online: 28 March 2019
Change Date: 25 May 2019
Change Type: Correction
Change Details: Study NCT01519323 (A study of vemurafenib in pediatric patients with stage IIIC or stage IV melanoma harbouring BRAFV600 mutations) was included in a table listing ongoing clinical trials of adjuvant therapies for pediatric melanoma (Table 1) in error. The study was in fact closed early due to low enrollment as correctly noted in section 4 of the article.
Compliance with Ethical Standards
:
: This work was funded by the Dermatology Foundation and the Society for Pediatric Dermatology (EBH).
: Elena B. Hawryluk’s spouse has received stock from Foundation Medicine Inc. and salary and stock from Gritstone Oncology. Elena B. Hawryluk has received authorship honorarium from UpToDate, Inc. Haya S. Raef and Alison M. Friedmann, MD, MSc, have no conflicts of interest that might be relevant to the contents of this manuscript.